Clinical Trials Browser

capivasertib × Breast × 1 year × Clear all

Breast Neoplasms, Melanoma

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

540 enrolled

Breast

Breast Neoplasms

NCT07281833 2026-02-27

CAPIcorn

Phase 3 Recruiting

250 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

300 enrolled

Breast

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

Phase 3 Active not recruiting

101 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

923 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01992952 2025-11-26

FAKTION

Phase 1/2 Active not recruiting

149 enrolled

Breast

Estrogen Receptor Positive Breast Cancer

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

ReDiscover-2

CAPIcorn

AMTEC IIT: Phase 2 Multiarm Study in TNBC

BEGONIA

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

CAPItrue

CAPItana

ELEVATE

CaptAin

CAPItello-290

DB-08

FAKTION

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules